Edition:
United Kingdom

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.32EUR
23 Jul 2019
Change (% chg)

-- (--)
Prev Close
€2.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
57,947
52-wk High
€3.30
52-wk Low
€2.28

Latest Key Developments (Source: Significant Developments)

Transgene Raises EUR 48.7 Million Gross In Rights Issue
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Transgene SA ::SUCCESS OF TRANSGENE’S €48.7 MILLION RIGHTS ISSUE.ISSUANCE OF 20,816,366 NEW SHARES AT A SUBSCRIPTION PRICE OF €2.34 PER NEW SHARE.TOTAL NET PROCEEDS OF THE RIGHTS ISSUE ARE EXPECTED TO BE AROUND €47.0 MILLION.  Full Article

Transgene Launches A Rights Issue For An Amount Of Up To 50 Million Euros
Friday, 14 Jun 2019 

June 14 (Reuters) - TRANSGENE SA ::LAUNCHES A RIGHTS ISSUE FOR AN AMOUNT OF UP TO €50 MILLION.SUBSCRIPTION RATIO: 1 NEW SHARE FOR 3 EXISTING SHARES.SUBSCRIPTION PRICE: €2.34 PER NEW SHARE.RIGHTS TRADING PERIOD: FROM JUNE 18, 2019 TO JUNE 25, 2019 (INCLUSIVE).SUBSCRIPTION PERIOD: FROM JUNE 20, 2019 TO JUNE 27, 2019 (INCLUSIVE).INSTITUT MÉRIEUX (THROUGH TSGH) HAS UNDERTAKEN TO SUBSCRIBE UP TO 75% OF THE NEW SHARES.DASSAULT BELGIQUE AVIATION HAS UNDERTAKEN TO SUBSCRIBE AT LEAST UP TO ITS CURRENT PARTICIPATION OF 4.7%.IF THE RIGHTS ISSUE IS REALISED ONLY UP TO 75%, THE COMPANY ESTIMATES THAT THE PROCEEDS OF THE TRANSACTION WOULD ENABLE IT TO MAINTAIN ITS CASH HORIZON THROUGH THE END OF 2021.  Full Article

Transgene Cash Position At End-Q1 9.1 Million Euros
Monday, 13 May 2019 

May 13 (Reuters) - TRANSGENE SA ::EUR 9.1 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2019.KEY CLINICAL TRIALS CONFIRMED TO READOUT IN H2 2019.€20 MILLION REVOLVING CREDIT FACILITY SECURED WITH NATIXIS.TRANSGENE EXPECTS ITS CASH BURN FOR 2019 TO BE BETWEEN EUR 15 MILLION AND EUR 20 MILLION.Q1 OPERATING REVENUE EUR 1.9 MILLION VERSUS EUR 1.8 MILLION YEAR AGO.HAS EXTENDED ITS FINANCIAL VISIBILITY TO Q4 2020.CONFIRMS THAT IT EXPECTS READOUTS FROM ITS KEY CLINICAL TRIALS IN SECOND HALF OF 2019.  Full Article

Transgene Receives FDA Clearance To Commence Clinical Development In Ovarian Cancer For TG4050
Monday, 13 May 2019 

May 13 (Reuters) - TRANSGENE SA ::TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™ INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL DEVELOPMENT IN OVARIAN CANCER.TRANSGENE RECEIVES FDA IND CLEARANCE FOR LEAD MYVAC™ INDIVIDUALIZED IMMUNOTHERAPY, TG4050, TO COMMENCE CLINICAL DEVELOPMENT IN OVARIAN CANCER.RECEIVED INVESTIGATIONAL NEW DRUG (IND) CLEARANCE FROM FDA TO PROCEED WITH A PHASE 1 CLINICAL TRIAL OF ITS LEAD MYVAC™ CANDIDATE TG4050.PHASE 1 CLINICAL TRIAL WILL EVALUATE SAFETY AND TOLERABILITY OF TG4050 IN PATIENTS WITH OVARIAN, FALLOPIAN OR PERITONEAL SEROUS CELL CARCINOMA.STUDY, SPONSORED BY TRANSGENE, WILL BE CO-FINANCED BY TRANSGENE AND ITS PARTNER NEC.PHASE 1 CLINICAL TRIAL, EXPECTED TO START IN H2 2019.  Full Article

Transgene Secures A 20 Million Euros Revolving Credit Facility With Natixis
Monday, 18 Mar 2019 

March 18 (Reuters) - TRANSGENE SA ::TRANSGENE SECURES A €20 MILLION REVOLVING CREDIT FACILITY WITH NATIXIS.CREDIT FACILITY WILL HAVE A 30-MONTH TERM AND TRANSGENE WILL BE ABLE TO DRAW ON AND REPAY FACILITY AT ITS DISCRETION.CEO: "WITH THIS NEW LOAN FACILITY, WE NOW HAVE FUNDS NEEDED TO SUPPORT OUR CLINICAL AND PRE-CLINICAL ACTIVITIES UNTIL MID-2020".  Full Article

Transgene Announces NEOVIVA Project Is Awarded A Grant Of 5.2 Million Euros
Wednesday, 13 Mar 2019 

March 13 (Reuters) - TRANSGENE SA ::TRANSGENE - NEOVIVA PROJECT SUPPORTING THE DEVELOPMENT OF MYVAC™ AWARDED A €5.2 MILLION GRANT FROM BPIFRANCE’S “INVESTMENTS FOR THE FUTURE” PROGRAMME.NEOVIVA PROJECT WILL RECEIVE EUR 5.2 MILLION OVER FIVE-YEAR DURATION OF PROGRAM FROM BPIFRANCE, OF WHICH TRANSGENE WILL RECEIVE EUR 2.6 MILLION.TWO PROOF OF CONCEPT CLINICAL TRIALS ARE BEING PREPARED IN EUROPE AND US FOR TREATMENT OF HPV-NEGATIVE HEAD AND NECK CANCERS AND OVARIAN CANCER.THESE ARE EXPECTED TO START IN H2 2019.  Full Article

Transgene To Start Clinical Development Of TG4050
Tuesday, 5 Mar 2019 

March 5 (Reuters) - TRANSGENE SA ::TRANSGENE TO START CLINICAL DEVELOPMENT OF LEAD MYVACTM INDIVIDUALIZED IMMUNOTHERAPY, TG4050, IN 2019, UNDER ITS PARTNERSHIP WITH NEC.BOTH STUDIES WILL BE CO-FUNDED BY TRANSGENE AND NEC.TG4050 IS A NEOANTIGEN THERAPEUTIC VACCINE DEVELOPED FOR INDIVIDUAL PATIENTS, BASED ON SPECIFIC MUTATIONS IDENTIFIED IN PATIENT'S OWN TUMOR.TWO CLINICAL TRIALS IN OVARIAN CANCER AND HEAD AND NECK CANCER PATIENTS WILL START IN 2019.  Full Article

Transgene Completes Safety And Tolerability Assessment In Phase 1B Part Trial In Hpv-Positive Cancer Patients
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - TRANSGENE SA ::TRANSGENE COMPLETES SAFETY AND TOLERABILITY ASSESSMENT OF TG4001 IN COMBINATION WITH AVELUMAB IN PHASE 1B PART OF TRIAL IN HPV-POSITIVE CANCER PATIENTS.ON TRACK WITH PHASE 2 PART OF STUDY: FIRST PATIENTS ENROLLED.OBJECTIVES FROM THE PHASE 1B STUDY SUCCESSFULLY MET.ON TRACK WITH THE PHASE 2 PART OF THE STUDY: FIRST PATIENTS ENROLLED.PRELIMINARY EFFICACY DATA EXPECTED IN 2H 2019.CLINICAL TRIAL IN COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER.  Full Article

Transgene Completes Safety And Tolerability Assessment Of TG4001
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Transgene SA ::TRANSGENE COMPLETES SAFETY AND TOLERABILITY ASSESSMENT OF TG4001 IN COMBINATION WITH AVELUMAB IN PHASE 1B PART OF TRIAL IN HPV-POSITIVE CANCER PATIENTS.OBJECTIVES FROM THE PHASE 1B STUDY SUCCESSFULLY MET.ON TRACK WITH THE PHASE 2 PART OF THE STUDY: FIRST PATIENTS ENROLLED.PRELIMINARY EFFICACY DATA EXPECTED IN 2H 2019.CLINICAL TRIAL IN COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER.FIRST DATA FROM THIS TRIAL ON THE ACTIVITY OF THE COMBINATION ARE EXPECTED DURING THE SECOND HALF OF 2019..  Full Article

Transgene: Positive Results Of TG1050 Phase 1 Clinical Trial In Chronic Hepatitis B
Monday, 12 Nov 2018 

Nov 12 (Reuters) - TRANSGENE SA ::POSITIVE RESULTS FROM PHASE 1 CLINICAL TRIAL OF TG1050 IN CHRONIC HEPATITIS B.PRIMARY END-POINT REACHED.TG1050 TRIGGERS T CELL-BASED IMMUNE RESPONSES.NEW PRECLINICAL DATA CLEARLY SUPPORT FURTHER INVESTIGATION OF TG1050 IN COMBINATION WITH ANTIVIRALS OR IMMUNOMODULATORS.NEW AND ENCOURAGING PRECLINICAL DATA SHOWING IMPROVED ANTIVIRAL ACTIVITY OF TG1050 WHEN ADMINISTERED IN COMBINATION WITH EITHER ANTIVIRALS OR IMMUNOMODULATORS IN HBV-PERSISTENT MICE.  Full Article

French and Benelux stocks-Factors to watch

July 3 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.